Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2018

Results From the STOMP-CSC Trial

Roger A. Goldberg, MD, MBA

Show Description +

Roger A. Goldberg, MD, MBA, shares first-time results from the randomized, double-masked, placebo-controlled STOMP-CSC clinical trial of short-term oral mifepristone for the treatment of central serous chorioretinopathy.

Posted: 5/01/2018

Keywords:

Central Serous Choroidopathy, CSC

Up Next

Five-Year Rates of Diabetic Retinopathy Progression

Five-Year Rates of Diabetic Retinopathy Progression

Andrew A. Moshfeghi, MD, MBA

A New Approach to Managing Macular Holes?

A New Approach to Managing Macular Holes?

Daniel Su, MD

A Future Role in Retina for Stem Cell and Gene Therapy?

A Future Role in Retina for Stem Cell and Gene Therapy?

Baruch D. Kuppermann, MD, PhD, Nathan C. Steinle, MD

Predictive Data From the HAWK and HARRIER Studies

Predictive Data From the HAWK and HARRIER Studies

A New Approach to Deviation Mapping for Retinal Perfusion

A New Approach to Deviation Mapping for Retinal Perfusion

Richard B. Rosen, MD

Early Experiences and Outcomes With Pneumatic Retinopexy vs. Future Use

Early Experiences and Outcomes With Pneumatic Retinopexy vs. Future Use

Glenn C. Yiu, MD, PhD

Baseline Features and Treatment Outcomes in Wet AMD

Baseline Features and Treatment Outcomes in Wet AMD

Nathan C. Steinle, MD

Digital Disruptions in Ophthalmology

Digital Disruptions in Ophthalmology

John B. Miller, MD, Roger A. Goldberg, MD, MBA

Getting Better at Treating Diabetic Retinopathy

Getting Better at Treating Diabetic Retinopathy

Nadia K. Waheed, MD, MPH, William F. Mieler, MD

DME Treatment Patterns

DME Treatment Patterns

Jeffrey R. Willis, MD, PhD

Quarterly Dosing and AMD: A Cross-Trial Comparison

Quarterly Dosing and AMD: A Cross-Trial Comparison

David A. Eichenbaum, MD

Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy

Real-World Outcomes of nAMD Treated With Anti-VEGF Therapy

Thomas A. Ciulla, MD, MBA

Back to All Videos

Results From the STOMP-CSC Trial

Roger A. Goldberg, MD, MBA

Roger A. Goldberg, MD, MBA, shares first-time results from the randomized, double-masked, placebo-controlled STOMP-CSC clinical trial of short-term oral mifepristone for the treatment of central serous chorioretinopathy.

Posted: 5/01/2018

Keywords:

Central Serous Choroidopathy, CSC

Please log in to leave a comment.

Comments

Ahmed Mofreh

7 years ago

Interesting Sir. You did not comment on the difference in results between dose 300 and dose 900 mg daily

More From ARVO: 2018 Coverage

Five-Year Rates of Diabetic Retinopathy Progression

Five-Year Rates of Diabetic Retinopathy Progression

Andrew A. Moshfeghi, MD, MBA

A New Approach to Managing Macular Holes?

A New Approach to Managing Macular Holes?

Daniel Su, MD

A Future Role in Retina for Stem Cell and Gene Therapy?

A Future Role in Retina for Stem Cell and Gene Therapy?

Baruch D. Kuppermann, MD, PhD, Nathan C. Steinle, MD

Predictive Data From the HAWK and HARRIER Studies

Predictive Data From the HAWK and HARRIER Studies

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2018.